Tag Archives: Antagonist

FDA Approves Qulipta (atogepant) Oral CGRP Receptor Antagonist for the Preventive Treatment of Migraine

[unable to retrieve full-text content]NORTH CHICAGO, Ill., Sept. 28, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved Qulipta (atogepant) for the preventive treatment of episodic migraine in adults.1 Qulipta is the first… Drugs.com – New Drug Approvals